Literature DB >> 21327910

Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Natig Gassanov1, Nasser Semmo2, Mariam Semmo3, Amir M Nia1, Uwe Fuhr4, Fikret Er5.   

Abstract

Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V(1a)R-mediated vasoconstriction and V(2)R-induced water retention represent a potentially attractive target of therapy for edematous diseases. Experimental and clinical evidence suggests beneficial effects of AVP receptor antagonists by increasing free water excretion and serum sodium levels. This review provides an update on the therapeutic implication of newly developed AVP receptor antagonists in respective disorders, such as chronic heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21327910     DOI： 10.1007/s00228-011-1006-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  78 in total

1.  Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas.

Authors:  Viviane Folny; Danielle Raufaste; Ludovit Lukovic; Brigitte Pouzet; Pierrick Rochard; Marc Pascal; Claudine Serradeil-Le Gal
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-05-07       Impact factor: 4.310

2.  Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.

Authors:  Douglas M Heuman; Souheil G Abou-Assi; Adil Habib; Leslie M Williams; R Todd Stravitz; Arun J Sanyal; Robert A Fisher; Anastasios A Mihas
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

3.  OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.

Authors:  Y Yamamura; S Nakamura; S Itoh; T Hirano; T Onogawa; T Yamashita; Y Yamada; K Tsujimae; M Aoyama; K Kotosai; H Ogawa; H Yamashita; K Kondo; M Tominaga; G Tsujimoto; T Mori
Journal:  J Pharmacol Exp Ther       Date:  1998-12       Impact factor: 4.030

4.  Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.

Authors:  Alexander L Gerbes; Veit Gülberg; Pere Ginès; Guy Decaux; Peter Gross; Hassan Gandjini; Jacques Djian
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

5.  Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure.

Authors:  T Yatsu; Y Tomura; A Tahara; K Wada; T Kusayama; J Tsukada; T Tokioka; W Uchida; O Inagaki; Y Iizumi; A Tanaka; K Honda
Journal:  Eur J Pharmacol       Date:  1999-07-09       Impact factor: 4.432

6.  Conivaptan: promise of treatment in heart failure.

Authors:  Mohammad Z Hoque; Pradeep Arumugham; Nazmul Huda; Nitin Verma; Mitul Afiniwala; Darshak H Karia
Journal:  Expert Opin Pharmacother       Date:  2009-09       Impact factor: 3.889

7.  Arginine vasopressin-mediated cardiac differentiation: insights into the role of its receptors and nitric oxide signaling.

Authors:  Natig Gassanov; Marek Jankowski; Bogdan Danalache; Donghao Wang; Ryszard Grygorczyk; Uta C Hoppe; Jolanta Gutkowska
Journal:  J Biol Chem       Date:  2007-02-13       Impact factor: 5.157

Review 8.  Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review.

Authors:  S L Vanhees; R Paridaens; J F Vansteenkiste
Journal:  Ann Oncol       Date:  2000-08       Impact factor: 32.976

Review 9.  Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.

Authors:  Catrin Palm; Frank Pistrosch; Kay Herbrig; Peter Gross
Journal:  Am J Med       Date:  2006-07       Impact factor: 4.965

10.  Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis.

Authors:  D G Bichet; V J Van Putten; R W Schrier
Journal:  N Engl J Med       Date:  1982-12-16       Impact factor: 91.245
View more
  13 in total

1.  Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.

Authors:  Maiko Namba; Akira Hiramatsu; Hiroshi Aikata; Kenichiro Kodama; Shinsuke Uchikawa; Kazuki Ohya; Kei Morio; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Tomokazu Kawaoka; Masataka Tsuge; Michio Imamura; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2019-09-04       Impact factor: 7.527

2.  Region-specific changes in transient receptor potential vanilloid channel expression in the vasopressin magnocellular system in hepatic cirrhosis-induced hyponatraemia.

Authors:  T P Nedungadi; F R Carreño; J D Walch; C S Bathina; J T Cunningham
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

3.  Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation.

Authors:  Kimikazu Yakushijin; Katsuya Yamamoto; Keiji Kurata; Yoshiharu Miyata; Seiji Kakiuchi; Hideo Tomioka; Yuriko Kawamori-Iwamoto; Yumiko Inui; Yukinari Sanada; Atsuo Okamura; Tohru Murayama; Hiroshi Matsuoka; Hironobu Minami
Journal:  Int J Hematol       Date:  2013-01-08       Impact factor: 2.490

4.  Prediction of molecular interactions and physicochemical properties relevant for vasopressin V2 receptor antagonism.

Authors:  Ania de la Nuez Veulens; Yoanna M Álvarez Ginarte; Rolando E Rodríguez Fernandez; Fabrice Leclerc; Luis A Montero Cabrera
Journal:  J Mol Model       Date:  2022-01-07       Impact factor: 1.810

5.  Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent.

Authors:  Nicole K Littlejohn; Rick B Siel; Pimonrat Ketsawatsomkron; Christopher J Pelham; Nicole A Pearson; Aline M Hilzendeger; Beth A Buehrer; Benjamin J Weidemann; Huiping Li; Deborah R Davis; Anthony P Thompson; Xuebo Liu; Martin D Cassell; Curt D Sigmund; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-27       Impact factor: 3.619

6.  Conivaptan therapy in an infant with severe hyponatremia and congestive heart failure.

Authors:  Raj Sahu; Duraisamy Balaguru; Vandana Thapar; Ikram Haque; Chi Pham-Peyton; J Timothy Bricker
Journal:  Tex Heart Inst J       Date:  2012

7.  Tolvaptan therapy for massive edema in a patient with nephrotic syndrome.

Authors:  Masaki Shimizu; Sayaka Ishikawa; Yusuke Yachi; Masahiro Muraoka; Yuko Tasaki; Hidenori Iwasaki; Mondo Kuroda; Kazuhide Ohta; Akihiro Yachie
Journal:  Pediatr Nephrol       Date:  2013-11-19       Impact factor: 3.714

Review 8.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

Review 9.  Current and future G protein-coupled receptor signaling targets for heart failure therapy.

Authors:  Ashley Siryk-Bathgate; Samalia Dabul; Anastasios Lymperopoulos
Journal:  Drug Des Devel Ther       Date:  2013-10-11       Impact factor: 4.162

10.  Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure.

Authors:  Shuichi Kitada; Shohei Kikuchi; Hiroo Sonoda; Atsuhiro Yoshida; Nobuyuki Ohte
Journal:  J Int Med Res       Date:  2016-10-27       Impact factor: 1.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.